Indications and management of implantable cardioverter-defibrillator therapy in childhood hypertrophic cardiomyopathy A position statement from the AEPC Working Group on Basic Science, Genetics and Myocardial Disease and the AEPC Working Group on Cardiac Dysrhythmias and Electrophysiology

• Published in: Cardiology in the young Vol. 33; no. 5; pp. 681 - 698
• Main Authors: Kaski, Juan Pablo, Kammeraad, Janneke A.E., Blom, Nico A., Happonen, Juha-Matti, Janousek, Jan, Klaassen, Sabine, Limongelli, Giuseppe, Östman-Smith, Ingegerd, Sarquella Brugada, Georgia, Ziolkowska, Lidia
• Format: Journal Article
• Language: English
• Published: 01.05.2023
• ISSN: 1047-9511; 1467-1107
• DOI: 10.1017/S1047951123000872

Abstract Sudden cardiac death is the most common mode of death during childhood and adolescence in hypertrophic cardiomyopathy, and identifying those individuals at highest risk is a major aspect of clinical care. The mainstay of preventative therapy is the implantable cardioverter-defibrillator, which has been shown to be effective at terminating malignant ventricular arrhythmias in children with hypertrophic cardiomyopathy but can be associated with substantial morbidity. Accurate identification of those children at highest risk who would benefit most from implantable cardioverter-defibrillator implantation while minimising the risk of complications is, therefore, essential. This position statement, on behalf of the Association for European Paediatric and Congenital Cardiology (AEPC), reviews the currently available data on established and proposed risk factors for sudden cardiac death in childhood-onset hypertrophic cardiomyopathy and current approaches for risk stratification in this population. It also provides guidance on identification of individuals at risk of sudden cardiac death and optimal management of implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy.